UNITED STATES OF AMERICA —Biopharmaceutical developer PDS Biotechnology has entered into a private investment in public equity agreement to raise up to $22.55 million. The funding round is anchored by Nant Capital, whose founder, Dr. Patrick Soon-Shiong, will join the board of directors along with an additional designee, contingent on maintaining a 15% beneficial ownership threshold. The financing structure is divided into an initial closing of approximately $11.55 million through equity shares, pre-funded warrants, and common warrants, followed by a potential $11 million milestone closing triggered by the submission of a Phase 3 trial protocol to regulatory authorities.
PDS Biotechnology is a clinical-stage biopharmaceutical firm based in New Jersey that develops targeted immunotherapies designed to stimulate specific immune responses against various cancers, utilizing proprietary platform technologies such as Versamune and specialized immunocytokines.
This capital commitment provides vital runway for advancing late-stage clinical programs targeting hard-to-treat solid tumors, particularly metastatic colorectal cancers that have historically resisted standard immunotherapies. By securing strategic backing from prominent industry leaders, the organization gains both financial liquidity to repay debt and operational resources to progress core drug candidates into registrational trials.
The transaction highlights sustained investor interest in targeted oncology assets and novel immunocytokine platforms. It also demonstrates how strategic partnerships between specialized biotechnology firms and established healthcare investors can accelerate clinical-stage assets toward commercialization while managing capital requirements in competitive therapeutic markets.
For the broader pharmaceutical and healthcare sector, the development reflects an ongoing focus on combination therapies aimed at overcoming immune resistance in gastrointestinal and HPV-related malignancies. The agreement also provides option rights for exclusive licensing negotiations regarding secondary therapeutic assets, illustrating structured risk-sharing models in drug development financing.
